“We assign greater weight to evidence produced by randomized clinical trial design” than to the findings offered by the “case series [that] were available,”

From a statement by the Centers for Medicare & Medicaid Services, explaining its rejection of a reimbursement request, “CMS: ‘no’ to FDG-PET coverage, for lack of assessment criteria,” p.4.

No Comments